Arvinas (ARVN) Net Cash Flow Growth (3y) (2020 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 4.55% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 52.78% |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 29.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.60% |
| Mar 31, 2026 | -46.39% |
| Dec 31, 2025 | 41.06% |
| Sep 30, 2025 | -32.60% |
| Jun 30, 2025 | 3.14% |
| Mar 31, 2025 | 24.88% |
| Dec 31, 2024 | 28.14% |
| Sep 30, 2024 | -33.19% |
| Jun 30, 2024 | 30.61% |
| Mar 31, 2024 | 2.63% |
| Dec 31, 2023 | -26.54% |
| Sep 30, 2023 | -30.02% |
| Jun 30, 2023 | -39.74% |
| Mar 31, 2023 | 22.05% |
| Dec 31, 2022 | -159.21% |
| Sep 30, 2022 | 270.67% |
| Jun 30, 2022 | 55.66% |
| Mar 31, 2022 | -56.01% |
| Dec 31, 2021 | -266.22% |
| Sep 30, 2021 | 317.80% |